EUCTR2007-004316-31-GB进行中（未招募）1 期
A randomised, double-blind, vehicle controlled, single centre, parallel group, comparative study of the efficacy of penciclovir 10 mg/g (1%) cream in preventing the appearance of classical lesions in recurrent cold sore sufferers. - Penciclovir 1% Cream Efficacy Study
ovartis Consumer Health S.A.0 个研究点目标入组 0 人开始时间: 2008年9月2日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Be known to be a cold sore sufferer presenting a prodromal stage followed by classical lesions;
- •2. Have prodromal symptoms (tingling, burning) within 8 hours before randomisation. The presence of the cold sore has to be determined thermographically: An increase of at least 0.5°C in comparison with the controlateral side of the lips has to be observed.
- •3. Present pain due to a cold sore at baseline (intensity =30 mm on a Visual Analogue
- •Scale (VAS) of 100 mm.
- •4. Sign the written informed consent form prior to enrolment in the trial;
- •5. Be aged 18 to 75 years;
- •6. If female of child-bearing potential, have a negative urine pregnancy test prior to inclusion;
- •7. Be a male or non-pregnant, non-lactating female. Women of child-bearing potential
- •have to use acceptable methods of contraception which are surgical sterilisation (e.g., bilateral tubal ligation, vasectomy), hormonal contraception (implantable, patch, oral), double-barrier methods (any double combination of: IUD, male or female condom with spermicidal gel, diaphragm, sponge, cervical cap) and sterilised partners by vasectomy or other means. Total abstinence may be considered as acceptable at the discretion of the investigator in cases where the age, career, lifestyle, or sexual orientation of the subject ensures compliance. Periodic abstinence (e.g., calendar, ovulation, symptothermal,post-ovulation methods) and withdrawal are not acceptable methods of contraception.
- •Reliable contraception should be maintained throughout the study. Women of non childbearing potential have to meet the following definition of post-menopausal status: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels >40 mIU/m or 6 weeks post surgical bilateral oophorectomy with or without hysterectomy;
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. If female, are pregnant, planning pregnancy or lactating;
- •2. Have a known hypersensitivity to penciclovir or any ingredients of the vehicle;
- •3. Have already ongoing classical cold sore lesions at the baseline visit;
- •4. Have taken any cold sore product, analgesic or NSAID in the 24 hours before the
- •baseline visit;
- •5. Have applied a cosmetic lip balm on their lips in the 12 hours before the baseline
- •thermographic assessment;
- •6. Have a moustache or beard;
- •7. Are known to be immunosuppressed (acquired, congenital or therapeutic);
- •8. Have been involved in any investigational protocol within the 30 days prior to the trial;
- •9. Have evidence or history of drug or alcohol abuse;
- •10. Are a member or relative of the trial site staff or an employee of the trial site or Sponsor.
研究者
相似试验
进行中（未招募）
1 期
A randomized, double-blind, vehicle controlled, single center, intra-individual comparative study of the efficacy and safety of diclofenac sodium 1 mg/g (0.1%) gel in subjects with painful UV-induced erythema - Diclofenac sodium 1 mg/g (0.1%) gelEUCTR2006-004524-36-FRovartis Consumer Health SA
已完成
不适用
A double blind, randomised, vehicle-controlled, safety and tolerance study of topical PSK 3841 solution at 5% administered twice daily over four weeks to healthy Caucasian males with androgenetic alopeciaAndrogenetic alopecia.Skin and Connective Tissue DiseasesAndrogenetic alopeciaISRCTN49873657ProStrakan Pharmaceuticals (France)60
进行中（未招募）
1 期
A double-blind, randomized, vehicle-controlled clinical multi-center study to evaluate the efficacy and safety of N-Acetyl-GED-0507-34-LEVO gel, 2 and 5%, applied once daily for 12 weeks in patients with facial acne vulgarisfacial acne vulgarisMedDRA version: 20.0Level: PTClassification code 10000496Term: AcneSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2018-003307-19-DEPPM SERVICES S.A.450
进行中（未招募）
1 期
A double-blind, randomized, vehicle-controlled clinical multi-center study to evaluate the efficacy and safety of N-Acetyl-GED-0507-34-LEVO gel, 2 and 5%, applied once daily for 12 weeks in patients with facial acne vulgarisfacial acne vulgarisMedDRA version: 20.0Level: PTClassification code 10000496Term: AcneSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2018-003307-19-ITPPM SERVICES S.A.450
进行中（未招募）
1 期
A double-blind, randomized, vehicle-controlled clinical multi-center study to evaluate the efficacy and safety of N-Acetyl-GED-0507-34-LEVO gel, 2 and 5%, applied once daily for 12 weeks in patients with facial acne vulgarisfacial acne vulgarisMedDRA version: 20.0Level: PTClassification code 10000496Term: AcneSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2018-003307-19-PLPPM SERVICES S.A.450